Volume 63, Issue 5 pp. 751-757
CLINICAL RESEARCH ARTICLE

Developing outcome measures of disease activity in pediatric myasthenia

Devin E. Prior MD

Devin E. Prior MD

Department of Neurology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA

Search for more papers by this author
Baillee A. Cooper MS

Baillee A. Cooper MS

Tufts University School of Medicine, Boston, Massachusetts, USA

Search for more papers by this author
Bo Zhang PhD

Corresponding Author

Bo Zhang PhD

Department of Neurology and ICCTR Biostatistics and Research Design Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA

Correspondence

Partha S. Ghosh MD, Department of Neurology, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115.

Email: [email protected]

Bo Zhang PhD, Department of Neurology and ICCTR Biostatistics and Research Design Center, Boston Children's Hospital and Harvard Medical School, 21 Autumn St, Suite 323, Boston, MA 02115.

Email: [email protected]

Search for more papers by this author
Partha S. Ghosh MD

Corresponding Author

Partha S. Ghosh MD

Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA

Correspondence

Partha S. Ghosh MD, Department of Neurology, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115.

Email: [email protected]

Bo Zhang PhD, Department of Neurology and ICCTR Biostatistics and Research Design Center, Boston Children's Hospital and Harvard Medical School, 21 Autumn St, Suite 323, Boston, MA 02115.

Email: [email protected]

Search for more papers by this author
First published: 18 February 2021
Citations: 1

Abstract

Introduction

Pediatric myasthenia encompasses juvenile myasthenia gravis (JMG) and congenital myasthenic syndrome (CMS), which are chronic disorders with fluctuating symptoms amenable to medical therapy. Disease activity and treatment response may be difficult to assess, but, unlike adults, outcome measures have not been developed in children.

Methods

The study was performed in children (0-18 years of age) at the neuromuscular center of a pediatric hospital over a 3-year period. Patients were recruited prospectively as part of their routine clinical care. Demographic data, diagnosis (JMG/CMS), and the following scales were recorded at each visit: Myasthenia Gravis Foundation of America (MGFA) class, Myasthenia Gravis Composite (MGC), and Pediatric Myasthenia–Quality of Life 15 (PM-QOL15).

Results

Thirty-three patients (24 JMG, 9 CMS) were included in the study, 22 had two or more visits. We established known-groups validity of the MGC and PM-QOL15 scores as compared with the MGFA class. To establish concurrent validity, we constructed a receiver-operating characteristic curve and calculated threshold values of MGC and PM-QOL15 with optimal sensitivity and specificity for identifying a patient with more severe (MGFA III or higher) disease. Finally, we demonstrated the concordance between the MGC and PM-QOL15 by their statistically significant positive Pearson and Spearman correlations.

Discussion

Our study suggests that MGC and PM-QOL15 are important disease outcome measures in pediatric myasthenia that are easy to administer and provide reliable assessment of disease activity in the clinic setting. Further studies are needed to validate their use for pediatric clinical research trials.

CONFLICT OF INTEREST

P.S.G. has received consulting fees from CVS Caremark, Catalyst Pharmaceuticals, Sarepta, and PTC. The remaining authors declare no potential conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me